Dear friends of MVMD,
I hope this note finds you well and that you are enjoying this amazing summer we are having.
This morning, we released a formal business update media release summarizing some of MVMD’s key advancements over the first half of the year. The full release is available on our website at mvmd.com, but I wanted to personally share a few highlights of the progress being made across our divisions.
I recently read a post by Arlene Dickinson on LinkedIn that captures a reality every entrepreneur eventually encounters, and it resonated strongly with me. She wrote that building a business will always take longer, cost more, and require more than planned. That is not pessimism, it’s reality. And it’s a reality that I have come to fully appreciate over the past year.
Patience in this context isn’t about standing still. It’s about carefully building the structures, relationships, validation, and capabilities needed to scale. While our progress might seem measured, I believe it is this disciplined approach that gives MVMD the greatest opportunity to create meaningful and sustainable shareholder value.
As you’ll see in this update, the past several months has been a period of meaningful advancement across our business lines, with tangible progress and foundational strength that I believe set the stage for MVMD’s successful commercialization. While it has required both patience and focus, I am very proud of our team and the significant progress being made.
NUTRACEUTICALS
Our Quicksome™ technology continues to demonstrate its versatility and commercial potential. One of our key licensees, Circadian Wellness, reported USD $193,000 in sales from its Eons Dialed and Eons Deeper Sleep products in the April–June period. This represents meaningful growth compared to prior periods and reflects continued market acceptance of our Quicksome™ technology in commercial products.
Another key highlight in our nutraceutical work is the proprietary testosterone-support project with a U.S.-based multi-level marketing client. The formulation uses a highly standardized fenugreek glycoside ingredient that has been clinically demonstrated to increase total and biologically active free testosterone. The product has been successfully integrated into a Quicksome™ quick-dissolve tablet and has shown positive support for testosterone levels in documented trials. Testosterone is well known to impact muscle mass, strength, energy, vitality, libido, and spermatogenesis, and I believe this category represents a significant commercial opportunity for MVMD. The MLM Client has completed multiple rounds of product feedback regarding dissolution and flavor, with commercial terms anticipated this year. A white-label version is also planned for manufacturing for broader distribution by the end of September.
As an aside, I personally participated in a trial of this testosterone product, supported by pre- and post-blood draws from January through March this year, and I can confirm I think it is outstanding. I’ll share more on my experience and results in a future update.
The broader nutraceutical pipeline also includes formulations for energy, lean metabolism, focus, stress, and anxiety support, which are now production-ready through our GMP manufacturing partner. Our “Mountains Of…” brand remains an important tool for business development, supported by expanded trademark protection across multiple categories.
AGRICULTURE
The Agrarius plant signaling technology continues to demonstrate strong and repeatable performance across multiple geographies and crops. We are now entering a new phase of our validation and commercialization strategy in Latin America (LATAM), following completion of an extensive cycle of professional field trials in Brazil across key crops, including corn, sugarcane, soybeans, potatoes, and citrus, alongside an thourough evaluation program with soybean farmers in high-productivity environments.
Our agronomists have worked closely with certified third-party agricultural testing partners, academic institutions, and farmers to conduct product trials, including detailed metabolic and physiological analysis of Agrarius-treated crops. Recent trial results continue to validate the efficacy of the Agrarius product and support planned product adoption and commercialization. A sample of recently achieved key trial outcomes includes:
- Corn: +14.8% yield in Dourados and +11.2% in Santa Cruz (UNESP trials)
- Sugarcane: +8–12 tons/ha yield (+10% average), +15% sugar yield, -47% pest damage (Agroquatro A.S trials)
- Soybeans: +6.34 sacs/ha average yield increase across 14 farmer validation trials; +15.61% productivity in CESB competition field
- Potatoes: +18.49% productivity increase in June 2025 harvest
- Citrus: +5.29% productivity increase; satellite analysis indicates up to +15% potential (confirmation at harvest)
These results are very exciting and support our broad adoption discussions with larger agricultural operators, reinforced by our innovative Performance Guarantee Program that links payment to measurable results in the field.
One of the most significant developments in LATAM is the launch of the FEDEGAN grass productivity program in Colombia. FEDEGAN is the national cattle growers’ federation, representing over 43 million hectares of cattle pastureland. This program is being conducted in seven regions and evaluates productivity, nutritional content, and growth cycles of multiple grass types when treated with Agrarius versus control plots. Managed in partnership with local agronomists and technical directors, the study will run through calendar 2026, with preliminary results expected in 2025.
Additional professional testing is underway on cotton, coffee, and citrus, alongside second-cycle validations for sugarcane and broad farmer-led trials for wheat and barley.
HUSBANDRY ANIMAL / AQUATIC SPECIES
In Bangladesh, approximately 200 tonnes of Soluvec™ 1% coated fish feed have been manufactured and distributed through five local distributors. While royalty revenues have been below expectations due to market disruptions, including Cyclone Remal’s impact on the fishing industry, the underlying technical performance remains strong.
Soluvec™ continues to demonstrate measurable advantages in stability, bioavailability, and application and global interest remains high based on initial business development conversations with key prospects. MVMD has filed Quicksol™ and Soluvec™ patent protection in 12 additional markets beyond the United States, including Canada, China, India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil, Peru, Argentina, and Chile. This positions us for future expansion into other high-priority markets in line with resource allocation.
LOOKING AHEAD
The consistent theme across all three divisions is readiness. The work we are doing today in technical validation, regulatory clearances, licensing, and commercial agreements, is designed to position MVMD for sustainable growth as these programs mature. We have entered the commercialization phase, and our focus is now on ensuring continued intelligent capital deployment and that scaling is managed effectively.
Thank you for your continued trust and support as we advance MVMD’s mission of “More Life.”
